எலியட் ஃபார்ஸ்டர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from எலியட் ஃபார்ஸ்டர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In எலியட் ஃபார்ஸ்டர் Today - Breaking & Trending Today

F-star Therapeutics, Inc.: F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update


F-star Therapeutics, Inc.: F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 17, 2021
(NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces first quarter 2021 financial results and provides a corporate update.
Strengthens balance sheet with successful closing of
$65 million public offering of common stock and;
Received $9.2 million in net proceeds under its at-the-market equity offering program
LAG-3 and PD-(L)1 co-targeting validation with LAG-3 validated in late-stage clinical trial as third checkpoint inhibitor pathway
FS118
FS222 presentation at AACR on the importance of tuning both affinity and avidity for differentiation ....

United States , United Kingdom , Helen Shik , Lindsey Trickett , Darlene Deptula Hicks , Eliot Forster , European Patent Office , Nature Communications , Drug Administration , Company To Host Conference Call , Horizon Technology Finance Corporation , Research Development , American Association For Cancer Research , Merck Kga , Therapeutics Inc , Merck Kgaa , Vp Investor Relations Communications , Shik Communications , Securities Exchange , Host Conference Call Today , F Star Therapeutics , Chief Financial Officer , American Association , Cancer Research , Annual Meeting , Tetravalent Bispecific Antibody Targeting ,

F-star Therapeutics, Inc.: F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration


(0)
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 01, 2021(NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised its option to develop an additional bispecific program under the ongoing collaboration with F-star.
This is the third option to license a preclinical program that Merck KGaA, Darmstadt, Germany has exercised in the ongoing collaboration with F-star. Merck KGaA, Darmstadt, Germany and F-star originally entered into a collaboration agreement in 2019 with the first option to license. In July 2020, Merck KGaA, Darmstadt, Germany brought the second program from the collaboration into its pipeline, and today has exercised its third option, taking over future development and commercialization of the program. An undisclosed option exercise paymen ....

United Kingdom , Helen Shik , Lindsey Trickett , Eliot Forster , Merck Kga , Therapeutics Inc , Vp Investor Relations Communications , Merck Kgaa , Shik Communications , Securities Exchange , F Star Therapeutics , Securities Exchange Act , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , ஒன்றுபட்டது கிஂக்டம் , எலியட் ஃபார்ஸ்டர் , மெர்க் க்க , சிகிச்சை இன்க் , வ்ப் முதலீட்டாளர் உறவுகள் தகவல்தொடர்புகள் , பத்திரங்கள் பரிமாற்றம் , எஃப் நட்சத்திரம் சிகிச்சை , பத்திரங்கள் பரிமாற்றம் நாடகம் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஆண்டு அறிக்கை , காலாண்டு அறிக்கைகள் ,